

10 February 2026

INDEX	Up/Down	Percentage	Points	Index Closing
S&P BSE SENSEX	▲	0.25%	208.17	84273.92
NIFTY 50	▲	0.26%	67.85	25935.15
S&P BSE 500	▲	0.25%	94.11	37207.34

Index	Open	High	Low	Close	52 W High	52 W Low
SENSEX	84,210.00	84,482.95	84,063.47	84,273.92	86,159.02	71,425.01
NIFTY	25,922.65	25,989.45	25,870.45	25,935.15	26,373.20	21,743.65

SENSEX Gainers	18	NIFTY Gainers	27
SENSEX Losers	12	NIFTY Losers	23

Exchange	Advances	Declines	Advance/Decline Ratio	Unchanged
BSE	2366	1524	1.55	255
NSE	1295	889	1.46	23

Top 5 SENSEX Drivers				Top 5 Gainers & Losers (X – Sensex)			
Gainers	(%)	Losers	(%)	Gainers	(%)	Losers	(%)
Eternal Ltd	5.19%	HCL Technologies Ltd	-1.86%	Kaycee Industries Ltd	20.00%	Sharp Investments Ltd	-11.76%
Tata Steel Ltd	2.89%	Bajaj Finance Ltd	-1.80%	Nilachal Refractories Ltd	19.98%	Barak Valley Cements Ltd	-10.56%
Mahindra And Mahindra Ltd	1.79%	Bharti Airtel Ltd	-1.36%	Pavna Industries Ltd	19.96%	Asian Warehousing Ltd	-10.20%
Power Grid Corporation of	1.69%	Asian Paints Ltd	-0.77%	Lumax Industries Ltd	19.96%	Pearl Global Industries L	-10.11%
Tech Mahindra Ltd	1.66%	HDFC Bank Ltd	-0.55%	Orient Beverages Ltd	19.36%	Roni Households Ltd	-10.00%
Top 5 NIFTY Drivers				Top 5 Gainers & Losers (X – Nifty)			
Gainers	(%)	Losers	(%)	Gainers	(%)	Losers	(%)
Eternal Ltd	5.19%	HCL Technologies Ltd	-2.03%	Pavna Industries Ltd	20.00%	Pearl Global Industries L	-10.57%
Tata Steel Ltd	2.90%	Bajaj Finance Ltd	-1.82%	Lumax Industries Ltd	20.00%	Jubilant Agri and Consume	-10.35%
Oil and Natural Gas Corpo	1.88%	Dr Reddy's Laboratories L	-1.55%	Abm International Ltd	19.99%	Loyal Textile Mills Ltd	-10.00%
Mahindra And Mahindra Ltd	1.87%	Shriram Finance Ltd	-1.33%	Laxmi Cotspin Ltd	19.97%	Barak Valley Cements Ltd	-9.97%
Bajaj Auto Ltd	1.79%	Bharti Airtel Ltd	-1.31%	Kshitij Polyline Ltd	19.82%	Spacenet Enterprises Indi	-9.89%

**Note:** - The above calculations are based on Closing Prices and not on Last Traded Prices.

**Aurobindo Pharma plunged 7.9%, over 3-month low post Q3 results:**

Share price of Aurobindo Pharma plunged 7.9% to 1106 in today's intra-day trade after the company announced December 2025 quarter (Q3FY26) results on Monday after market hours. Aurobindo reported a single digit 8.4% year-on-year (YoY) growth in revenue at ₹8,646 crore due to softness in the US (43% of the revenues) which grew 2% to ₹3,739 crore. Europe formulations revenue increased by 27.4% YoY to ₹2,703 crore, while growth markets revenue remained flat YoY at ₹865 crore. EBITDA grew 9% YoY to ~₹1,773 crore while EBITDA margins increased 11 bps to 20.5%. Profit after tax grew 7.6% YoY to ₹910 crore. Aurobindo on February 6, 2026 said that the United States Food and Drug Administration (US FDA) inspected Unit-III, a formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly-owned subsidiary of Aurobindo, situated at Sangareddy (Telangana), from January 27 to February 06, 2026. The inspection concluded with 11 observations. Aurobindo highlighted that the observations were procedural in nature, and the company aims to address these observations with the stipulated timeline of USFDA regulatory framework.

**Samvardhana Motherson extended gains, up 6.1% after Q3 net profit rises 21%:**

Samvardhana Motherson International share price rose to ₹131.90 over 6% today after the company released Q3FY26 results. Samvardhana Motherson International share price extended gains after it reported an increase in the net profit for the October–December (Q3FY26) quarter. The net profit increased 21% on year to ₹1,061 crore from ₹879 crore in the same period a year ago (Q3FY25). Lower finance costs and higher contribution from joint ventures and associates supported the improvement in the profit after tax (PAT), the company said in the exchange filing. Samvardhana Motherson International recognised a one-time loss of ₹25 crore due to implement the changes to the new labour code. Additionally, the company also incurred ₹12-crore loss due to the adjustment of exceptional expenses pertaining to provisions made in respect to business transformative measures in the central and western Europe. Samvardhana Motherson International saw a 14% Y-o-Y rise in the topline due to the impact of Atsumitec acquisition, organic growth, commodity and favourable forex conditions. The revenue for the third quarter stood at ₹31,409 crore versus ₹27,666 crore last year. Ebitda increased 9.7% on year to ₹3,042 crore in the December quarter from ₹2,776 crore because the benefits of transformative measures in the multi-purpose plant division supported the operational improvement, the company said in the exchange filing.

**Amber Enterprises share price rose 6.9% after Q3 net profit jumps 128% YoY:**

Amber Enterprises India share price jumped nearly 6.9% in today's session to 7530 after the company reported a significant increase in the third-quarter net profit (Q3FY26). The company reported a 128% Y-o-Y increase in the net profit during the third quarter (Q3FY26). The net profit increased to ₹84 crore versus ₹37 crore in the same period a year ago (Q3FY25). Amber Enterprises India's revenue increased 38% on year to ₹2,943 crore in the December quarter from ₹2,133 crore, the company said in the exchange filing. The company's EBITDA increased 53% on year to ₹247 crore from ₹162 crore. Meanwhile, in the third quarter, Amber Enterprises India incurred a one-time loss of ₹9 crore due to the changes in the new labour code. In the October–December period, Amber Enterprises India received strategic approvals under the Electronic Manufacturing Component Scheme (ECMS) for two of its key subsidiaries. Ascent-K Circuit, a joint venture with Korea Circuits, has been granted approval for ₹3,200 crore investment to manufacture high-density interconnect printed-circuit board (PCBs). Simultaneously Shogini Technoarts secured an approval for an ₹500 crore project focused on multi-layer PCB applications. The approvals, sanctioned in the presence of the IT Minister, marked a significant step in Amber Enterprises India's transition toward becoming a backwards-integrated electronics major.

**Pfizer shares jumped 11.2% on posting healthy Q3 show:**

Pfizer's share price jumped 11.2%, logging an intra-day high at ₹5,296 after the company released its Q3FY26 numbers on Monday, after market hours. In the December quarter, Pfizer reported an 11% rise in consolidated net profit to ₹1,41.84 crore, compared to ₹127.6 crore a year ago. The company's revenue from operations was up 19.8% to ₹645.03 crore during the quarter under review compared to ₹537.99 crore year-on-year (Y-o-Y). The company's total income for the quarter came in at ₹683.24 crore, as compared to ₹580.75 crore a year ago. Total expenses stood at ₹433.09 crore, compared to ₹408.31 crore year-on-year (Y-o-Y). That apart, in December 2025, Pfizer launched a new medication, Rimegepant ODT, in India for migraine treatment in adults with a previous insufficient response to triptan, the usual drug used for migraine relief.

**Bata India shares jumped 8.3% on posting Q3 results; PAT up 13% YoY:**

share price jumped 8.3%, registering an intra-day high at ₹958 after the company released its Q3FY26 numbers on Monday, after market hours. In the December quarter, Bata India Ltd reported a 12.61% rise in consolidated net profit to ₹66.1 crore, compared to ₹58.7 crore a year ago. The company's revenue from operations was up 2.81% to ₹944.68 crore during the quarter under review compared to ₹918.79 crore year-on-year (Y-o-Y). Premium brands (Hush Puppies and Power) continued to scale, while fresh sales contribution improved sequentially, indicating better merchandising execution. The Zero Base Merchandising (ZBM) program was expanded to over 400 stores, supporting higher revenue per sq. ft. and improved in-store experience. Inventory quality and freshness improved alongside an 11% reduction in gross inventory, reflecting tighter control on buying and replenishment. The company added 27 franchise stores during the quarter, continuing its asset-light expansion strategy.



## Disclosures and Disclaimer

**Disclosures and Disclaimers:** This Report is published by Sunidhi Securities & Finance Limited (hereinafter referred to as "Sunidhi") SEBI Research Analyst Registration Number: INH000001329 for private circulation. Sunidhi is a registered Stock Broker with National Stock Exchange of India Limited, BSE Limited and Metropolitan Stock Exchange of India Limited in cash, derivatives and currency derivatives segments. It is also having registration as a Depository Participant with CDSL.

Sunidhi has other business divisions with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets.

Sunidhi or its associates has not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. Sunidhi or analyst or his relatives do not hold any financial interest in the subject company. Associates may have such interest in its ordinary course of business as a distinct and independent body. Sunidhi or its associates or Analyst do not have any conflict or material conflict of interest at the time of publication of the research report with the company covered by Analyst.

Sunidhi or its associates / analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. Sunidhi or its associates has not received any compensation or other benefits from the company covered by Analyst or third party in connection with the research report. Analyst has not served as an officer, director or employee of subject company and Sunidhi / analyst has not been engaged in market making activity of the subject company.

Analyst or his relatives do not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report. Sunidhi or its associates may have investment positions in the stocks recommended in this report, which may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report. However, Sunidhi is maintaining Chinese wall between other business divisions or activities. Analyst has exercised due diligence in checking correctness of details and opinion expressed herein is unbiased.

This report is meant for personal informational purposes and is not be construed as a solicitation or financial advice or an offer to buy or sell any securities or related financial instruments. While utmost care has been taken in preparing this report, we claim no responsibility for its accuracy. Recipients should not regard the report as a substitute for the exercise of their own judgment. Any opinions expressed in this report are subject to change without any notice and this report is not under any obligation to update or keep current the information contained herein. Past performance is not necessarily indicative of future results. This report accepts no liability whatsoever for any loss or damage of any kind arising out of the use of all or any part of this report.

Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment.

The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. Sunidhi or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Sunidhi has not independently verified all the information contained within this document. Accordingly, we cannot testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document. While Sunidhi endeavors to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Neither Sunidhi nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in

connection with the use of this information.

### Sunidhi Securities & Finance Ltd. – Research Analyst – INH000001329

Kalpataru Inspire, Unit.1, 8th floor, Opp. Grand Hyatt Hotel, Santacruz East, Mumbai-400055

Bombay Stock Exchange (BSE)	National Stock Exchange of India Ltd (NSE)	Metropolitan Stock Exchange of India Limited (MSEI)
Registration no. INZ000169235	Registration no. INZ000169235	Registration no. INZ000169235
Compliance Officer Name:	Mr. Mahesh Desai	Phone No: 9122-66771777